Cellular Pathobiology Unit/DPS, Cellular Neurobiology Research Branch, National Institute on Drug Abuse, National Institutes of Health, DHHS., 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
Curr Neuropharmacol. 2005 Oct;3(4):267-80. doi: 10.2174/157015905774322516.
Although originally proposed as a subtype of opioid receptors, the sigma receptor is now confirmed to be a non-opioid receptor that binds diverse classes of psychotropic drugs. Sigma receptors are subdivided into two subtypes, sigma-1 and sigma-2. The sigma-1 receptor is a 25-kDa protein possessing one putative transmembrane domain and an endoplasmic reticulum retention signal. Sigma-1 receptors are highly expressed in deeper laminae of the cortex, olfactory bulb, nuclei of mesencephalon, hypothalamus, and Purkinje cells in the brain. Sigma-1 receptors are predominantly localized at the endoplasmic reticulum of both neurons and oligodendrocytes. From behavioral studies, sigma-1 receptors were shown to be involved in higher-ordered brain functions including memory and drug dependence. The actions mediated by sigma-1 receptors at the cellular level can be considered either as acute or chronic. The acute actions include the modulation of ion channels (i.e., K+ channel, NMDA receptors, IP3 receptors) and the sigma-1 receptor translocation. Chronic actions of sigma-1 receptors are basically considered to be the result of an up- or down regulation of the sigma-1 receptor itself. For example, the upregulation of sigma-1 receptors per se, even without exogenous ligands, promotes cellular differentiation and reconstitution of lipid microdomains (lipid rafts) in cultured cells. These findings together suggest that sigma-1 receptors might possess a constitutive biological activity, and that sigma-1 receptor ligands might merely work as modulators of the innate activity of this protein. Recent in vitro and in vitro studies strongly point to the possibility that sigma-1 receptors participate in membrane remodeling and cellular differentiation in the nervous system.
虽然最初被提议为阿片受体的亚型,但sigma 受体现在被确认为结合各种精神药物的非阿片受体。sigma 受体分为两种亚型,sigma-1 和 sigma-2。sigma-1 受体是一种 25kDa 的蛋白质,具有一个假定的跨膜结构域和内质网保留信号。sigma-1 受体在大脑皮质的更深层、嗅球、中脑核、下丘脑和浦肯野细胞中高度表达。sigma-1 受体主要定位于神经元和少突胶质细胞的内质网。从行为研究来看,sigma-1 受体参与包括记忆和药物依赖在内的高级大脑功能。sigma-1 受体在细胞水平介导的作用可被认为是急性或慢性的。急性作用包括离子通道的调制(即 K+通道、NMDA 受体、IP3 受体)和 sigma-1 受体的易位。sigma-1 受体的慢性作用基本上被认为是 sigma-1 受体自身的上调或下调的结果。例如,sigma-1 受体本身的上调,即使没有外源性配体,也能促进细胞分化和培养细胞中脂质微区(脂筏)的重建。这些发现共同表明,sigma-1 受体可能具有固有生物活性,而 sigma-1 受体配体可能只是作为该蛋白固有活性的调节剂起作用。最近的体外和体内研究强烈表明 sigma-1 受体可能参与神经系统中的膜重塑和细胞分化。